
Revolution Medicines' chief commercialization officer Mancini has sold $3.15m.
No additional details are provided.
Key Takeaways
Center
Coverage blindspot: Reporting on this development is currently concentrated in other segments of the media landscape.
Coverage blindspot: Reporting on this development is currently concentrated in other segments of the media landscape.
Get every side of the week's biggest story in your inbox.
Potential impact on Revolution Medicines
No attributed perspective yet — we only show quotes grounded in analysis.
Evaluated across 1 reporting source (0% Left · 100% Center · 0% Right)
Historical editorial baseline for Investing.com
Multi-factor accuracy index for Investing.com and related desks based on verifiable sourcing and editorial standards.
Factuality: High 100%
Ownership: Investing.com (Corporate)
Public conversation related to this story
Loading comments…